文献速递临床试验与 GCP流行病学与生物统计

中剂量与标准剂量预防性抗凝对COVID-19 ICU患者血栓事件、ECMO治疗或死亡的影响:INSPIRATION随机临床试验

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

INSPIRATION多中心随机试验在伊朗10个学术中心纳入ICU成人COVID-19患者,比较中剂量依诺肝素(1 mg/kg每日)与标准剂量(40 mg每日)预防性抗凝。结果不支持对未选择的ICU COVID-19患者常规经验性使用中剂量预防性抗凝。

要点

  • 中剂量与标准剂量预防性抗凝的30天复合终点无显著差异。
  • 中剂量组大出血未达非劣效标准,且严重血小板减少仅见于中剂量组。
  • 不支持对未选择的ICU COVID-19患者常规使用中剂量预防性抗凝。

核心结论

  • 在ICU成人COVID-19患者中,中剂量与标准剂量预防性抗凝相比,30天主要复合终点无显著差异。
  • 结果不支持对未选择的ICU COVID-19患者常规经验性使用中剂量预防性抗凝。

研究设计与样本

  • 多中心随机试验,2×2析因设计,在伊朗10个学术中心进行。
  • 纳入ICU成人COVID-19患者,中剂量依诺肝素1 mg/kg每日(n=276)与标准剂量依诺肝素40 mg每日(n=286)比较。
  • 600例随机患者中562例(93.7%)纳入主要分析;中位年龄62岁(IQR 50-71),女性237例(42.2%)。

主要发现

  • 大出血在中剂量组7例(2.5%),标准剂量组4例(1.4%);风险差1.1%(单侧97.5%CI -∞至3.4%),OR 1.83(单侧97.5%CI 0.00-5.93),未达非劣效标准(非劣效P>.99)。

关键数值与推荐

  • 主要疗效终点为30天内静脉或动脉血栓、体外膜氧合(ECMO)治疗或死亡的复合终点。
  • 大出血采用Bleeding Academic Research Consortium 3型或5型定义,非劣效界值为OR 1.8。
  • 严重血小板减少定义为血小板计数<20×10³/µL。

临床怎么用

  • 对未选择的ICU COVID-19患者,不应常规经验性使用中剂量预防性抗凝。
  • 中剂量预防性抗凝需警惕大出血和严重血小板减少风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Thrombotic events are commonly reported in critically ill patients with COVID-19. Limited data exist to guide the intensity of antithrombotic prophylaxis. OBJECTIVE: To evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU). DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized trial with a 2 × 2 factorial design performed in 10 academic centers in Iran comparing intermediate-dose vs standard-dose prophylactic anticoagulation (first hypothesis) and statin therapy vs matching placebo (second hypothesis; not reported in this article) among adult patients admitted to the ICU with COVID-19. Patients were recruited between July 29, 2020, and November 19, 2020. The final follow-up date for the 30-day primary outcome was December 19, 2020. INTERVENTIONS: Intermediate-dose (enoxaparin, 1 mg/kg daily) (n = 276) vs standard prophylactic anticoagulation (enoxaparin, 40 mg daily) (n = 286), with modification according to body weight and creatinine clearance. The assigned treatments were planned to be continued until completion of 30-day follow-up. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days, assessed in randomized patients who met the eligibility criteria and received at least 1 dose of the assigned treatment. Prespecified safety outcomes included major bleeding according to the Bleeding Academic Research Consortium (type 3 or 5 definition), powered for noninferiority (a noninferiority margin of 1.8 based on odds ratio), and severe thrombocytopenia (platelet count <20 ×103/µL). All outcomes were blindly adjudicated. RESULTS: Among 600 randomized patients, 562 (93.7%) were included in the primary analysis (median [interquartile range] age, 62 [50-71] years; 237 [42.2%] women). The primary efficacy outcome occurred in 126 patients (45.7%) in the intermediate-dose group and 126 patients (44.1%) in the standard-dose prophylaxis group (absolute risk difference, 1.5% [95% CI, -6.6% to 9.8%]; odds ratio, 1.06 [95% CI, 0.76-1.48]; P = .70). Major bleeding occurred in 7 patients (2.5%) in the intermediate-dose group and 4 patients (1.4%) in the standard-dose prophylaxis group (risk difference, 1.1% [1-sided 97.5% CI, -∞ to 3.4%]; odds ratio, 1.83 [1-sided 97.5% CI, 0.00-5.93]), not meeting the noninferiority criteria (P for noninferiority >.99). Severe thrombocytopenia occurred only in patients assigned to the intermediate-dose group (6 vs 0 patients; risk difference, 2.2% [95% CI, 0.4%-3.8%]; P = .01). CONCLUSIONS AND RELEVANCE: Among patients admitted to the ICU with COVID-19, intermediate-dose prophylactic anticoagulation, compared with standard-dose prophylactic anticoagulation, did not result in a significant difference in the primary outcome of a composite of adjudicated venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days. These results do not support the routine empirical use of intermediate-dose prophylactic anticoagulation in unselected patients admitted to the ICU with COVID-19. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04486508.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021. PMID: 33734299. doi:10.1001/jama.2021.4152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。